Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder October 17, 2024 at 4:30 PM EDT Listen to webcast Supporting Materials View Presentation 614.1 KB